JP2019505533A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505533A5
JP2019505533A5 JP2018540799A JP2018540799A JP2019505533A5 JP 2019505533 A5 JP2019505533 A5 JP 2019505533A5 JP 2018540799 A JP2018540799 A JP 2018540799A JP 2018540799 A JP2018540799 A JP 2018540799A JP 2019505533 A5 JP2019505533 A5 JP 2019505533A5
Authority
JP
Japan
Prior art keywords
crystal form
ray powder
crystalline
diffraction pattern
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540799A
Other languages
English (en)
Japanese (ja)
Other versions
JP6889171B2 (ja
JP2019505533A (ja
Filing date
Publication date
Priority claimed from CN201610082029.8A external-priority patent/CN107043379A/zh
Application filed filed Critical
Publication of JP2019505533A publication Critical patent/JP2019505533A/ja
Publication of JP2019505533A5 publication Critical patent/JP2019505533A5/ja
Application granted granted Critical
Publication of JP6889171B2 publication Critical patent/JP6889171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540799A 2016-02-05 2017-02-04 Tlr7アゴニスト結晶形a、その調製方法及び使用 Active JP6889171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN201610082029.8 2016-02-05
PCT/CN2017/072891 WO2017133684A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的晶型a、其制备方法和用途

Publications (3)

Publication Number Publication Date
JP2019505533A JP2019505533A (ja) 2019-02-28
JP2019505533A5 true JP2019505533A5 (cg-RX-API-DMAC7.html) 2020-02-27
JP6889171B2 JP6889171B2 (ja) 2021-06-18

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540799A Active JP6889171B2 (ja) 2016-02-05 2017-02-04 Tlr7アゴニスト結晶形a、その調製方法及び使用

Country Status (27)

Country Link
US (2) US10442811B2 (cg-RX-API-DMAC7.html)
EP (1) EP3412672B1 (cg-RX-API-DMAC7.html)
JP (1) JP6889171B2 (cg-RX-API-DMAC7.html)
KR (1) KR102393280B1 (cg-RX-API-DMAC7.html)
CN (2) CN107043379A (cg-RX-API-DMAC7.html)
AR (1) AR107548A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017215801B2 (cg-RX-API-DMAC7.html)
CA (1) CA3013518C (cg-RX-API-DMAC7.html)
CL (1) CL2018002092A1 (cg-RX-API-DMAC7.html)
DK (1) DK3412672T3 (cg-RX-API-DMAC7.html)
EA (1) EA035951B1 (cg-RX-API-DMAC7.html)
ES (1) ES2830443T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201644T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051399T2 (cg-RX-API-DMAC7.html)
IL (1) IL260968B (cg-RX-API-DMAC7.html)
LT (1) LT3412672T (cg-RX-API-DMAC7.html)
MX (1) MX374297B (cg-RX-API-DMAC7.html)
NZ (1) NZ744884A (cg-RX-API-DMAC7.html)
PH (1) PH12018501643A1 (cg-RX-API-DMAC7.html)
PL (1) PL3412672T3 (cg-RX-API-DMAC7.html)
PT (1) PT3412672T (cg-RX-API-DMAC7.html)
SG (1) SG11201806683UA (cg-RX-API-DMAC7.html)
SI (1) SI3412672T1 (cg-RX-API-DMAC7.html)
TW (1) TWI754629B (cg-RX-API-DMAC7.html)
UA (1) UA121161C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017133684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805186B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
EP3816166A4 (en) * 2018-05-25 2022-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
EP3937944A1 (en) * 2019-03-15 2022-01-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
SG11202111488YA (en) * 2019-04-23 2021-11-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Solid pharmaceutical composition comprising tlr7 agonist
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むmRNAワクチン
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
CN101304748A (zh) * 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
EP2670244B1 (en) * 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) * 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
EP2922547B1 (en) 2012-11-20 2017-03-08 Glaxosmithkline LLC Novel compounds
AU2013348217B2 (en) * 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
SMT201700378T1 (it) * 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
EA030603B1 (ru) * 2014-05-01 2018-08-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途

Similar Documents

Publication Publication Date Title
JP2019505533A5 (cg-RX-API-DMAC7.html)
JP2019504103A5 (cg-RX-API-DMAC7.html)
JP2019505532A5 (cg-RX-API-DMAC7.html)
JP2021530565A5 (cg-RX-API-DMAC7.html)
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
JP2014501282A5 (cg-RX-API-DMAC7.html)
JP2016121196A5 (cg-RX-API-DMAC7.html)
JP2017505329A5 (cg-RX-API-DMAC7.html)
JP2011512396A (ja) 新規な多形およびその調製方法
JP2013516473A5 (cg-RX-API-DMAC7.html)
JP2016537346A5 (cg-RX-API-DMAC7.html)
JP6378844B2 (ja) 第6結晶形ソホスブビルの調製方法
CN111004212A (zh) 一种制备尼古丁的方法
JP2018520147A5 (cg-RX-API-DMAC7.html)
JP2011500780A5 (cg-RX-API-DMAC7.html)
JP2017210488A5 (cg-RX-API-DMAC7.html)
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺
JP2022060192A5 (cg-RX-API-DMAC7.html)
CN112771052A (zh) 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2018522945A5 (cg-RX-API-DMAC7.html)
JP2015531354A5 (cg-RX-API-DMAC7.html)
CN106604916A (zh) 钾离子竞争性酸阻滞剂的晶型及其制备方法
JP2010502682A5 (cg-RX-API-DMAC7.html)
JP2018509421A5 (cg-RX-API-DMAC7.html)
JP2020500907A5 (cg-RX-API-DMAC7.html)